initiation of antiretroviral therapy in HIV-positive individuals. *JAIDS*. 2019;82:314–320.

2. Hyle EP, Scott JA, Sax PE, et al. Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States. *Clin Infect Dis*. 2019 [epub ahead of print].

3. Nakagawa F, Miners A, Smith CI, et al. Projected lifetime healthcare costs associated with HIV infection. *PLoS One*. 2015;10:e0125018.

4. Krentz HB, Ko K, Beckthold B, et al. The cost of antiretroviral drug resistance in HIV-positive patients. *Antivir Ther*. 2014;19:341–348.

5. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. *Ann Intern Med*. 2013;158:84–92.

6. Castro H, Pillay D, Sabin C, et al; Resistance UKCGoHD. Effect of mismatch of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. *BMC Med Res Methodol*. 2012;12:30.

7. Cento V, Perno CF. Two-drug regimens with disoproxil plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety. *J Glob Antimicrob Resist*. 2019. doi: 10.1016/j.jgar.2019.08.010.

8. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. *Lancet*. 2019;393:143–155.

9. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. *J Acquir Immune Defic Syndr*. 2003;32:292–297.

10. Delaugerre C, Chai X, Blanche S, et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. *Retrovirology*. 2009;6:85.

11. Jochimsen EM. Failures of zidovudine post-initiation of antiretroviral therapy in HIV-positive individuals. *JAIDS*. 2019;82:314–320.

12. Hyle EP, Scott JA, Sax PE, et al. Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States. *Clin Infect Dis*. 2019 [epub ahead of print].

3. Nakagawa F, Miners A, Smith CI, et al. Projected lifetime healthcare costs associated with HIV infection. *PLoS One*. 2015;10:e0125018.

4. Krentz HB, Ko K, Beckthold B, et al. The cost of antiretroviral drug resistance in HIV-positive patients. *Antivir Ther*. 2014;19:341–348.

5. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. *Ann Intern Med*. 2013;158:84–92.

6. Castro H, Pillay D, Sabin C, et al; Resistance UKCGoHD. Effect of mismatch of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. *BMC Med Res Methodol*. 2012;12:30.

7. Cento V, Perno CF. Two-drug regimens with disoproxil plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety. *J Glob Antimicrob Resist*. 2019. doi: 10.1016/j.jgar.2019.08.010.

8. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. *Lancet*. 2019;393:143–155.

9. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. *J Acquir Immune Defic Syndr*. 2003;32:292–297.

10. Delaugerre C, Chai X, Blanche S, et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. *Retrovirology*. 2009;6:85.

11. Jochimsen EM. Failures of zidovudine post-initiation of antiretroviral therapy in HIV-positive individuals. *JAIDS*. 2019;82:314–320.

12. Hyle EP, Scott JA, Sax PE, et al. Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States. *Clin Infect Dis*. 2019 [epub ahead of print].

3. Nakagawa F, Miners A, Smith CI, et al. Projected lifetime healthcare costs associated with HIV infection. *PLoS One*. 2015;10:e0125018.

4. Krentz HB, Ko K, Beckthold B, et al. The cost of antiretroviral drug resistance in HIV-positive patients. *Antivir Ther*. 2014;19:341–348.

5. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. *Ann Intern Med*. 2013;158:84–92.

6. Castro H, Pillay D, Sabin C, et al; Resistance UKCGoHD. Effect of mismatch of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. *BMC Med Res Methodol*. 2012;12:30.

7. Cento V, Perno CF. Two-drug regimens with disoproxil plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety. *J Glob Antimicrob Resist*. 2019. doi: 10.1016/j.jgar.2019.08.010.

8. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. *Lancet*. 2019;393:143–155.

9. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. *J Acquir Immune Defic Syndr*. 2003;32:292–297.

10. Delaugerre C, Chai X, Blanche S, et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. *Retrovirology*. 2009;6:85.

11. Jochimsen EM. Failures of zidovudine post-initiation of antiretroviral therapy in HIV-positive individuals. *JAIDS*. 2019;82:314–320.

12. Hyle EP, Scott JA, Sax PE, et al. Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States. *Clin Infect Dis*. 2019 [epub ahead of print].

3. Nakagawa F, Miners A, Smith CI, et al. Projected lifetime healthcare costs associated with HIV infection. *PLoS One*. 2015;10:e0125018.

4. Krentz HB, Ko K, Beckthold B, et al. The cost of antiretroviral drug resistance in HIV-positive patients. *Antivir Ther*. 2014;19:341–348.

5. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. *Ann Intern Med*. 2013;158:84–92.

6. Castro H, Pillay D, Sabin C, et al; Resistance UKCGoHD. Effect of mismatch of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. *BMC Med Res Methodol*. 2012;12:30.

7. Cento V, Perno CF. Two-drug regimens with disoproxil plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety. *J Glob Antimicrob Resist*. 2019. doi: 10.1016/j.jgar.2019.08.010.

8. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. *Lancet*. 2019;393:143–155.

9. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. *J Acquir Immune Defic Syndr*. 2003;32:292–297.

10. Delaugerre C, Chai X, Blanche S, et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. *Retrovirology*. 2009;6:85.

11. Jochimsen EM. Failures of zidovudine post-initiation of antiretroviral therapy in HIV-positive individuals. *JAIDS*. 2019;82:314–320.

12. Hyle EP, Scott JA, Sax PE, et al. Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States. *Clin Infect Dis*. 2019 [epub ahead of print].
studies or studies supported by ViiV Healthcare (generally designed to study dolutegravir use in late-stage pregnancy), 29 from spontaneous reports, and 1 from a ViiV Healthcare–sponsored clinical trial. Forty-three of the congenital abnormalities were cases of umbilical hernia, with 37 occurring in the DolPHIN-2 study (ongoing in Uganda and South Africa) investigating efficacy and safety of third-trimester dolutegravir exposure in pregnant HIV-infected women.¹³ The majority of the remaining cases was related to the nervous system (n = 14), cardiac system (n = 13), and musculoskeletal system (n = 8). Of the 116 reports of congenital abnormalities that provided information on the trimester of exposure, 49 were exposed to dolutegravir or dolutegravir/abacavir/lamivudine in the first trimester (including 33 cases exposed at conception), 20 in the second trimester, and 47 in the third trimester.

There have been 9 reported and confirmed cases of NTDs with mothers who were exposed to dolutegravir or dolutegravir/abacavir/lamivudine: 6 from the Tsepamo study (5 with exposure at conception and 1 with exposure to dolutegravir started during pregnancy; study data as of March 2019)⁶ and 3 spontaneous cases as of January 31, 2019 (1 from Namibia, reported in January 2017 and 2 from the United States, both reported in June 2018).

Of the 3 cases of NTDs reported spontaneously to ViiV Healthcare outside of the Tsepamo study, 1 case was from a woman in Namibia who had been receiving dolutegravir for several months before conception. Treatment with dolutegravir continued until an unspecified NTD was diagnosed in utero. No information was provided on concomitant medications or medical or family history. The other 2 cases were both from the United States and involved women who had taken dolutegravir/abacavir/lamivudine for ≥1 year before conception. In both cases, the NTDs (anencephaly, sacromeningocele) were diagnosed during prenatal ultrasound. Both infants were carried to term, 1 died after delivery, whereas the other was reported to be doing well after surgical closure of the sacromeningocele. Neither mother was reported to have taken folic acid supplementation preconception. Neither woman had taken medications recognized as associated with NTDs or had a current diagnosis of epilepsy or diabetes, although 1 had a history of seizures and 2 previous spontaneous abortions, and the other had a body mass index >30 kg/m², indicating a potentially elevated risk.

Although reporting postmarketing surveillance data is important, they are limited by the inability to calculate prevalence rates because the true denominator is not available and births without defects are underreported. Cumulative exposure to dolutegravir-containing products is estimated to be >1.3 million patient-years, but the number of women who have taken dolutegravir during pregnancy is unknown. Although the limitations of postmarketing surveillance data are well recognized, the number of spontaneous reports of NTDs with dolutegravir-containing regimens has

### Table 1. Cumulative Pregnancy Outcomes Reported After Maternal Exposure to Dolutegravir During a ViiV-Sponsored Study or Postmarketing Surveillance

| Outcome                                      | Dolutegravir Exposure | Dolutegravir/Abacavir/Lamivudine Exposure | Total |
|----------------------------------------------|-----------------------|------------------------------------------|-------|
| ViiV-sponsored studies                       |                       |                                          |       |
| Live infant, no apparent congenital anomaly  | 24                    | 9                                        | 33    |
| Live infant, congenital anomaly              | 1                     | 0                                        | 1     |
| Spontaneous abortion, no apparent congenital anomaly | 11                   | 3                                        | 14    |
| Ectopic pregnancy                            | 2                     | 0                                        | 2     |
| Elective termination, no apparent congenital anomaly | 15                   | 4                                        | 19    |
| Pregnancy ongoing                            | 5                     | 2                                        | 7     |
| Pregnancy outcome unknown/lost to follow-up  | 3                     | 1                                        | 4     |
| Total                                        | 61                    | 19                                       | 80    |
| Postmarketing surveillance                   |                       |                                          |       |
| Live infant, no apparent congenital anomaly  | 240                   | 74                                       | 314   |
| Live infant, congenital anomaly              | 89                    | 24                                       | 113   |
| Spontaneous abortion, congenital anomaly     | 3                     | 8                                        | 11    |
| Stillbirth, congenital anomaly               | 1                     | 1                                        | 2     |
| Elective termination, congenital anomaly     | 2                     | 5                                        | 7     |
| Spontaneous abortion, no apparent congenital anomaly | 51                   | 18                                       | 69    |
| Stillbirth, no apparent congenital anomaly   | 34                    | 0                                        | 34    |
| Ectopic pregnancy                            | 2                     | 2                                        | 4     |
| Elective termination, no apparent congenital anomaly | 22                   | 4                                        | 26    |
| Pregnancy ongoing                            | 108                   | 59                                       | 167   |
| Pregnancy outcome unknown/lost to follow-up  | 144                   | 89                                       | 233   |
| Total                                        | 696                   | 284                                      | 980   |

¹Data cutoff January 16, 2019.  
¹Includes published data from the Tsepamo study up to July 2018.  
¯Includes outcomes where it is unknown whether a congenital anomaly occurred.
been low when viewed in the context of global dolutegravir use and awareness of the NTD signal among prescribers since the Tsepamo study findings were first reported.

To detect associations of drug exposure with rare events like NTDs, ~2000 pregnancies with drug exposure collected in a structured manner are needed to determine a 3-fold increased probability of the event occurring. In 2018, the Botswana Birth Outcomes Surveillance study expanded to include surveillance from 8 to 18 sites, with plans to include data from an additional 1226 births of infants exposed to dolutegravir at conception. In addition, the Ministry of Health of Brazil, in partnership with the National Institutes of Health, Vanderbilt University, and the Oswaldo Cruz Foundation, has initiated a national, retrospective, observational cohort study to evaluate the incidence of NTDs after dolutegravir exposure during pregnancy, estimate the risk of NTDs in infants born to women receiving dolutegravir and raltegravir at conception, and evaluate factors associated with the risk of NTDs in infants born to women who received dolutegravir at conception. ViiV Healthcare is conducting or supporting several observational studies to assess dolutegravir use in pregnancy, including the APR, as well as the DOLOMITE-EPPIC and DOLOMITE-NEAT ID NETWORK studies that include European data. These emerging data will be critical in making a more definitive judgment about the potential risk of dolutegravir use during pregnancy.

It is important that the potential benefits of any ART during pregnancy are carefully weighed against the potential risks to the developing fetus, keeping in mind that untreated HIV infection during pregnancy has also been associated with adverse birth outcomes, including low birth weight, preterm birth, and stillbirth compared with HIV-negative controls. In addition, lack of ART or delayed ART initiation in pregnant women increases the risk of vertical transmission.

To further minimize this risk, full viral suppression by delivery is a vital treatment goal for pregnant HIV-infected women. Dolutegravir-based therapy in pregnancy is generally effective with a good maternal safety and tolerability profile. Overall, the rate of adverse birth outcomes following dolutegravir exposure after conception has been consistent with that observed for other ART regimens and the general population, but the potential association of dolutegravir exposure at the time of conception with the development of NTDs requires further study. Until the NTD signal is confirmed or refuted, ViiV Healthcare recommends that women of childbearing potential who are taking a dolutegravir-based regimen use effective contraception. If pregnancy occurs while taking a dolutegravir-based regimen and the pregnancy is confirmed within the first trimester, the benefits and risks of switching to an alternative regimen should be considered. For those women planning to become pregnant, switching to an appropriate alternative regimen, if possible, is recommended.

Treatment guidelines for HIV, including those from the US Department of Health and Human Services, recommend a similar approach and allow for dolutegravir use after the first 14 weeks of pregnancy. Updated guidelines from the World Health Organization in July 2019 now recommend that dolutegravir can be prescribed in all women of childbearing potential, including those planning pregnancy as well as during pregnancy, provided the woman is fully informed of the potential increased risk of NTDs (at conception and until the end of the first trimester). At this time, available data do not indicate any specific safety risk with dolutegravir use after the first trimester of pregnancy.

ACKNOWLEDGMENTS
Editorial assistance was provided under the direction of the authors by Jeffrey Stumpf, PhD, and Jennifer Rossi, MA, ELS, MedThink SciCom, and was funded by ViiV Healthcare.

Melissa Crawford, PhD
Jean van Wyk, MBChB, MFPM
Michael Aboud, MD
Vani Vannappagari, PhD
Beth Romach, PhD
Lloyd Curtis, MA, MRCP
Brian Wynne, MD
Annemieke de Ruiter, MD
Kimberly Smith, MD
Nassrin Payvandi, PhD

REFERENCES
1. Siegfried N, van der Merwe L, Brocklehurst P, et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011: CD003510.
2. Bailey H, Zash R, Rasi V, et al. HIV treatment in pregnancy. Lancet HIV. 2018;5:e457–e467.
3. Tivicay [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2019.
4. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379:979–981.
5. Zash R, Holmes L, Makhema J, et al. Surveillance for neural tube defects following antiretroviral exposure from conception. Presented at: 22nd International AIDS Conference; July 24, 2018; Amsterdam, the Netherlands.
6. Zash R, Holmes L, Disoko M, et al. Neural tube defects by antiretroviral and HIV exposure in the Tsepamo study, Botswana [MOAX0105LB]. Presented at: 10th IAS Conference on HIV Science; July 22, 2019; Mexico City, Mexico.
7. Wilde JJ, Petersen JR, Niswander L. Genetic, epigenetic, and environmental contributions to neural tube closure. Annu Rev Genet. 2014;48:583–611.
8. Zaganjor I, Sekkarie A, Tsang BL, et al. Describing the prevalence of neural tube defects worldwide: a systematic literature review. PLoS One. 2016;11:e0151586.
9. Greene ND, Copp AJ. Neural tube defects. Annu Rev Neurosci. 2014;37:221–242.
10. Cavallo P. Prevention of neural tube defects and proper folate periconceptional supplementation. J Perinat Med. 2008;24:40–41.
11. Copp AJ, Greene ND. Neural tube defects—disorders of neurulation and related embryonic processes. Wiley Interdiscip Rev Dev Biol. 2013;2:213–227.
12. Committee on Practice Bulletins-Obstetrics. Practice bulletin no. 187: neural tube defects. Obstet Gynecol. 2017;130:e279–e290.
13. Kintu K, Malaba T, Nakibuka J, et al; for the DolPhin-2 Study Group. RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: DolPHIN-2 [40 LB]. Presented at: Conference on Retroviruses and Opportunistic Infections; March 5, 2019; Seattle, WA.
14. Mofenson LM. Overview on toxicity monitoring and surveillance of DTG during pregnancy to inform treatment policy. Presented at: 22nd International AIDS Conference; July 24, 2018; Amsterdam, the Netherlands.
15. Benzaken AS. Brazil experience: active toxicity monitoring in adults and birth defect surveillance with DTG: country experience in monitoring new ARVs: focus on toxicity monitoring and surveillance of DTG during pregnancy to inform treatment policy. Presented at: 22nd International AIDS Conference; July 24, 2018; Amsterdam, the Netherlands.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
16. Vannappagari V, Thorne C; for APR and EPPICC. Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir. *J Acquir Immune Defic Syndr*. 2019;81:371–378.
17. ViiV Healthcare Study Register. *ViiV Study ID: 208613*. ViiV Healthcare UK Limited; 2019. Available at: https://www.viiv-studyregister.com/study/19664. Accessed May 30, 2019.
18. ClinicalTrials.gov. Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women. ClinicalTrials.gov; 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT03564613. Accessed May 30, 2019.
19. Wedi CO, Kirtley S, Hopewell S, et al. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. *Lancet HIV*. 2016;3:e33–e48.
20. British HIV Association. *British HIV Association Guidelines for the Management of HIV in Pregnancy and Postpartum 2018 (2019 Interim Update)*. British HIV Association; 2019. Available at: https://www.bhiva.org/file/sbf6d30be95deb/BHIVA-guidelines-for-the-management-of-HIV-in-pregnancy.pdf. Accessed May 30, 2019.
21. Dugdale CM, Ciarranello AL, Bekker LG, et al. Risks and benefits of dolutegravir- and efavirenz-based strategies for South African women with HIV of child-bearing potential: a modeling study. *Ann Intern Med*. 2019;170:614–625.
22. European AIDS Clinical Society. *EACS Guidelines Version 9.1*. European AIDS Clinical Society; 2018. Available at: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed May 30, 2019.
23. Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. *Lancet Glob Health*. 2018;6:e804–e810.
24. *Triumeq [package insert]*. Research Triangle Park, NC: ViiV Healthcare; 2019.
25. US Department of Health and Human Services. *Recommendations Regarding the Use of Dolutegravir in Adults and Adolescents With HIV Who Are Pregnant or of Child-Bearing Potential*. Department of Health and Human Services; 2018. Available at: https://aidsinfo.nih.gov/news/2109/recommendations-regarding-the-use-of-dolutegravir-in-adultsand-adolescents-with-hiv-who-are-pregnant-or-of-child-bearing-potential. Accessed May 30, 2019.
26. World Health Organization. *Update of Recommendations on First- and Second-Line Antiretroviral Regimens*. World Health Organization; 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1. Accessed August 19, 2019.